CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
about
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAberrant cell cycle regulation in cervical carcinoma.RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesionsInduction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.Loss of functional pRB is not a ubiquitous feature of B-cell malignanciesAlteration of p16 and p15 genes in human uterine tumoursAnalysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines.p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype.p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma.Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia.Expression of cyclin E in placentas with hydropic change and gestational trophoblastic diseases: implications for the malignant transformation of trophoblasts.
P2860
Q27022834-0EF8E169-8B73-4F28-961D-9AD952FA7708Q33607056-6422FD2A-7443-45ED-994C-73FFB344BEECQ34935948-F62A022B-92C8-40A1-9540-EFE02026398EQ35785959-598C0A5B-EA3E-41DB-9665-427200062F13Q36421683-E6925E7E-612F-45AB-A3F9-F6C4FE40E261Q36617740-112AF3E0-32F2-45E8-B836-5936DC1CFC7FQ36617950-966A4938-8FBD-40FA-8E95-BF38C93ADE81Q38471657-2383D797-E400-4F61-B199-3E04D2BF8C8EQ39337041-69B4AC4C-6841-4E4C-B01F-84EB41B47044Q42204969-5C81D5EB-0C28-4501-B431-BEEF259ED1F5Q43716774-7400664F-4729-45A2-BB8F-8BC529EFEE5AQ43919089-68FC5E1E-67FE-4E2E-A7BD-D2CA2C9C53B2Q44574851-A7087B4C-36F9-4FDE-93A4-C80B4933E260Q53388830-90B51454-DCEF-4E2F-B0DB-07486B501C38Q53407070-65FB442F-6B1B-4588-8418-2B58A465926C
P2860
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
@en
type
label
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
@en
prefLabel
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
@en
P2093
P356
P1476
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines
@en
P2093
B E Johnson
G A Otterson
J A Dipaolo
N C Popescu
P304
P356
10.1002/IJC.2910630214
P577
1995-10-01T00:00:00Z